The clinical impact of testing for biomarkers in gastric cancer patients: a real world cohort.
Karen van der SluisJohanna W van SandickJolanda M van DierenMarieke A VolleberghCecile GrootscholtenJosé G van den BergPetur SnaebjornssonKoen J HarteminkAlexander A F A VeenhofMyriam ChalabiLiudmila L KodachPublished in: Histopathology (2023)
In this real-world cohort, biomarker testing often affected treatment decisions. Although most dMMR and EBV+ tumors had a PD-L1 CPS≥5, not all patients with a high probability of treatment response are identified. Based on these results, a stepwise diagnostic strategy is proposed.